Company news

ProMIS Neurosciences Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

April 3, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

March 31, 2024

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

March 10, 2024

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

February 21, 2024

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

January 21, 2024

ProMIS Neurosciences, Inc. Announces Leadership Transition

January 2, 2024

ProMIS Neurosciences Announces Publication on Novel Target for ALS

December 19, 2023

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease

November 19, 2023

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

November 13, 2023

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

September 7, 2023

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 5, 2023

Satellos Expands Leadership Team with New CFO Appointment

September 4, 2023

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

August 20, 2023

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

August 13, 2023

ProMIS Showcases Preclinical Data at the Alzheimer’s Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer’s Pipeline

July 16, 2023

ProMIS Announces Completion of Continuance

July 13, 2023

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

July 9, 2023

ProMIS Neurosciences Holds Annual Meeting of Shareholders All Resolutions Approved

June 29, 2023

CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9: 30am Eastern Time

June 28, 2023

ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

May 14, 2023

ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease

May 7, 2023

Data Presented at American Academy of Neurology Annual Meeting on Novel Vaccine Design for Alzheimer’s Disease

April 24, 2023

ProMIS Neurosciences Presents Preclinical Data Highlighting Targeting of Toxic Misfolded Proteins in Alzheimer’s Disease and ALS at American Academy of Neurology Annual Meeting

April 23, 2023

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

April 9, 2023

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

March 28, 2023

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

March 12, 2023

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

March 12, 2023

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

March 7, 2023

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

March 7, 2023

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

November 13, 2022

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

October 11, 2022

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

September 12, 2022

← Newer news releases

Decks